These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 18690923)

  • 1. Evolving paradigms in pharmacovigilance.
    Brewster W; Gibbs T; Lacroix K; Murray A; Tydeman M; Almenoff J
    Curr Drug Saf; 2006 May; 1(2):127-34. PubMed ID: 18690923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovations for the future of pharmacovigilance.
    Almenoff JS
    Drug Saf; 2007; 30(7):631-3. PubMed ID: 17604419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
    Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
    Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacovigilance: Importance, concepts, and processes.
    Kumar A
    Am J Health Syst Pharm; 2017 Apr; 74(8):606-612. PubMed ID: 28235869
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacoepidemiology in the postmarketing assessment of the safety and efficacy of drugs in older adults.
    Hilmer SN; Gnjidic D; Abernethy DR
    J Gerontol A Biol Sci Med Sci; 2012 Feb; 67(2):181-8. PubMed ID: 21653991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Erice Manifesto: for global reform of the safety of medicines in patient care.
    Drug Saf; 2007; 30(3):187-90. PubMed ID: 17343426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacovigilance: methods, recent developments and future perspectives.
    Härmark L; van Grootheest AC
    Eur J Clin Pharmacol; 2008 Aug; 64(8):743-52. PubMed ID: 18523760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The new pharmacovigilance legislation in practice].
    Broekmans AW; Mol PG
    Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of the Methods to Obtain Paediatric Drug Safety Information: Spontaneous Reporting and Healthcare Databases, Active Surveillance Programmes, Systematic Reviews and Meta-analyses.
    Gentili M; Pozzi M; Peeters G; Radice S; Carnovale C
    Curr Clin Pharmacol; 2018; 13(1):28-39. PubMed ID: 29412117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods.
    Montastruc JL; Sommet A; Lacroix I; Olivier P; Durrieu G; Damase-Michel C; Lapeyre-Mestre M; Bagheri H
    Joint Bone Spine; 2006 Dec; 73(6):629-32. PubMed ID: 17110152
    [No Abstract]   [Full Text] [Related]  

  • 12. A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases.
    Coloma PM; Avillach P; Salvo F; Schuemie MJ; Ferrajolo C; Pariente A; Fourrier-Réglat A; Molokhia M; Patadia V; van der Lei J; Sturkenboom M; Trifirò G
    Drug Saf; 2013 Jan; 36(1):13-23. PubMed ID: 23315292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [From pharmacovigilance to pharmacoepidemiology and risk coordination].
    Montastruc JL
    Rev Med Interne; 2009 Dec; 30 Suppl 4():S281-90. PubMed ID: 19892443
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacoepidemiologic research in Australia: challenges and opportunities for monitoring patients with rheumatic diseases.
    Lu CY
    Clin Rheumatol; 2009 Apr; 28(4):371-7. PubMed ID: 19190976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specialist Cohort Event Monitoring studies: a new study method for risk management in pharmacovigilance.
    Layton D; Shakir SA
    Drug Saf; 2015 Feb; 38(2):153-63. PubMed ID: 25564333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New approaches to drug safety: a pharmacovigilance tool kit.
    Wise L; Parkinson J; Raine J; Breckenridge A
    Nat Rev Drug Discov; 2009 Oct; 8(10):779-82. PubMed ID: 19763106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
    Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
    Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Social Media Listening for Routine Post-Marketing Safety Surveillance.
    Powell GE; Seifert HA; Reblin T; Burstein PJ; Blowers J; Menius JA; Painter JL; Thomas M; Pierce CE; Rodriguez HW; Brownstein JS; Freifeld CC; Bell HG; Dasgupta N
    Drug Saf; 2016 May; 39(5):443-54. PubMed ID: 26798054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.